Photys Therapeutics

Photys Therapeutics

Verified
A proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function

Launch date
Employees
Ownership
Market cap
-
Net debt
-
Firm valuation
$300—450m (Dealroom.co estimates Sep 2022.)
Cambridge Massachusetts (HQ)
  • Edit

Recent News about Photys Therapeutics

Edit